Onderzoeker
Sylvia De Brakeleer
- Trefwoorden:Geneeskunde
- Disciplines:Moleculaire diagnostiek, Genetica, Kankerbiologie, Genetische predispositie, Analyse van next-generation sequence data
Affiliaties
- Observerende Klinische wetenschappen (Departement)
Lid
Vanaf8 apr 2019 → 28 jun 2019 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf14 aug 2015 → 28 jun 2016 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 jan 2014 → 28 jun 2019 - Laboratorium Moleculaire Oncologie (Onderzoeksgroep)
Lid
Vanaf1 jan 2010 → 22 mrt 2021 - Embryologie en Menselijke Genetica (Departement)
Lid
Vanaf1 mrt 2003 → 31 dec 2013
Publicaties
1 - 10 van 14
- CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition(2019)
Auteurs: Maxim Noeparast, Philippe Giron, Alfiah Noor, Rajendra Bahadur Shahi, Sylvia De Brakeleer, Carolien Eggermont, Hugo Vandenplas, Bram Boeckx, Diether Lambrechts, Jacques De Grève, et al.
Pagina's: 5933-5941 - The clinical characteristics of breast cancers with a familial risk in which no BRCA1/2 mutations were found are sometimes suggestive for a genetic etiology(2019)
Auteurs: Sofie Joris, Rajendra Bahadur Shahi, Sylvia De Brakeleer, Christel Fontaine, Maryse Bonduelle, Pauwels Ingrid, Erik Teugels, Jacques De Grève
- Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families(2019)
Auteurs: Rajendra Bahadur Shahi, Sylvia De Brakeleer, Ben Caljon, Ingrid Pauwels, Maryse Bonduelle, Sofie Joris, Christel Fontaine, Marian Vanhoeij, Sonia Van Dooren, Erik Teugels, et al.
- Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer(2018)
Auteurs: Maxim Noeparast, Philippe Giron, Sylvia De Brakeleer, Carolien Eggermont, Ulrike De Ridder, Erik Teugels, Jacques De Grève
Pagina's: 16110-16123 - An alternative model for (breast) cancer predisposition(2017)
Auteurs: Erik Teugels, Sylvia De Brakeleer
- Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib(2016)
Auteurs: Maxim Noeparast, Erik Teugels, Philippe Giron, Gil Verschelden, Sylvia De Brakeleer, Lore Decoster, Jacques De Grève
Pagina's: 60094-60108 - Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients(2016)
Auteurs: Sylvia De Brakeleer, Jacques De Grève, C Desmedt, Sofie Joris, Christos Sotiriou, M. Piccart, I Pauwels, Erik Teugels
Pagina's: 336-340 - Parp inhibitors(2016)
Auteurs: Leen Vanacker, I. Pauwels, E. Denayer, Sylvia De Brakeleer, Erik Teugels
Pagina's: 263-275 - Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma(2015)
Auteurs: Isabelle Vande Broek, Françoise Majois, Jean-François Baurain, Sylvie Rottey, Andrée Rorive, Johan de Mey, Sylvia De Brakeleer
Pagina's: 6893-6899 - Detection of EGFR-TK Domain-activating Mutations in NSCLC With Generic PCR-based Methods(2015)
Auteurs: Rajendra Bahadur Shahi, Sylvia De Brakeleer, Jacques De Grève, Caroline Geers, Pieter in 't Veld, Erik Teugels
Pagina's: 163-171
Gelinkte datasets
1 - 7 van 7
- Additional file 9: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 1: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 6: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 4: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 11: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 5: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 3: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)